Takahashi Y, Tobe K, Kadowaki H, Katsumata D, Fukushima Y, Yazaki Y, Akanuma Y, Kadowaki T
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Endocrinology. 1997 Feb;138(2):741-50. doi: 10.1210/endo.138.2.4910.
Insulin-like growth factor-I (IGF-I) improves glucose metabolism and growth in patients with leprechaunism. We investigated signal transduction through IGF-I receptor in comparison with epidermal growth factor (EGF) receptor in early passages of cultured skin fibroblasts from a normal subject and a patient with leprechaunism whose insulin receptor tyrosine kinase was almost nonexistent. Insulin receptor substrate-1 (IRS-1) became tyrosine-phosphorylated and bound growth factor receptor-bound protein 2 (GRB2) quickly by IGF-I. The association of Shc with GRB2 by IGF-I was detected by immunoblot with anti-Shc antibody but was hardly visible with antiphosphotyrosine antibody, which was in marked contrast to efficient tyrosine phosphorylation of Shc by EGF. However, the potency of IGF-I for DNA synthesis was far stronger than EGF, which was not parallel with the potency of these growth factors to activate Shc or MAP kinase. Rather, phosphatidylinositol (PI) 3-kinase activity, which was activated by IGF-I about 5- to 10-fold more strongly than EGF, appeared to correlate with mitogenesis. Signal transduction pathways following IGF-I receptor or EGF receptor activation were indistinguishable between the normal subject and the patient. Our results strongly suggest that in human skin fibroblasts, which represent a more physiological cell culture: 1) IRS-1, rather than Shc, is the major tyrosine-phosphorylated protein binding GRB2 in initial phase of IGF-I signaling; 2) mitogenic potency of receptor tyrosine kinases such as IGF-I receptor and EGF receptor may not be determined solely by the amount of Shc-GRB2 complex or the activity of MAP kinase; and 3) in contrast to previous reports, IGF-I and EGF receptor signalings are not defective in leprechaunism.
胰岛素样生长因子-I(IGF-I)可改善矮妖精貌综合征患者的葡萄糖代谢和生长情况。我们以一名正常受试者和一名胰岛素受体酪氨酸激酶几乎不存在的矮妖精貌综合征患者培养的皮肤成纤维细胞早期传代为研究对象,比较了胰岛素样生长因子-I受体(IGF-I受体)和表皮生长因子(EGF)受体的信号转导过程。胰岛素受体底物-1(IRS-1)被IGF-I迅速酪氨酸磷酸化,并与生长因子受体结合蛋白2(GRB2)结合。通过抗Shc抗体免疫印迹法检测到IGF-I使Shc与GRB2发生关联,但用抗磷酸酪氨酸抗体几乎检测不到,这与EGF使Shc高效酪氨酸磷酸化形成鲜明对比。然而,IGF-I促进DNA合成的能力远比EGF强,这与这些生长因子激活Shc或丝裂原活化蛋白激酶(MAP激酶)的能力并不平行。相反,磷脂酰肌醇(PI)3激酶活性似乎与有丝分裂相关,IGF-I对其激活的强度比EGF强约5至10倍。正常受试者和患者之间,IGF-I受体或EGF受体激活后的信号转导途径并无差异。我们的结果有力地表明,在更具生理学意义的人皮肤成纤维细胞培养中:1)在IGF-I信号传导的初始阶段,IRS-1而非Shc是与GRB2结合的主要酪氨酸磷酸化蛋白;2)受体酪氨酸激酶如IGF-I受体和EGF受体的促有丝分裂能力可能并非仅由Shc-GRB2复合物的量或MAP激酶的活性决定;3)与之前的报道相反,IGF-I和EGF受体信号传导在矮妖精貌综合征中并无缺陷。